Move by FTSE’s biggest company gains support of 99% of shareholders who voted in blow to London market
AstraZeneca, Daiichi Sankyo and Gilead report promising trial results in ‘triple negative’ breast cancer
Chief executive Pascal Soriot applauds the deal with Donald Trump as ‘a big win’ for US patients
Baxdrostat meets goals for patients with resistant hypertension and may generate sales of $5bn a year
AstraZeneca’s humbling blow to London highlights need for change in UK and elsewhere in Europe
HMRC will no longer reap benefit of share trading in FTSE 100’s largest company
One of UK’s largest companies says it intends to create a ‘global listing’
Government prepared to pay more for medicines, says Lord Patrick Vallance
Bristol Myers Squibb will sell its new schizophrenia treatment in the UK for $22,500 a year
Eli Lilly, Merck and AstraZeneca have all said in recent weeks that they plan to roll back investment
Ambassador’s meeting with chancellor Rachel Reeves came days before AstraZeneca and Merck paused projects in Britain
Voters in Guyana will decide how to spend around $40bn in oil revenues in the next five years
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre
NHS curbs on drug prices have alienated UK pharma companies and become self-defeating
US president threatens to ‘deploy every tool in our arsenal’ to protect Americans from ‘abusive drug prices’
Revenue rise comes as drugmaker plans $50bn US investment in face of looming tariff threat
Sector faces threat of levies as high as 200% on overseas imports
Drug group chief Pascal Soriot frustrated with UK but shareholders worry about country losing FTSE’s largest company
Ministers remain locked in talks with sector over future of clawback tax
Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments
Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year
Anglo-Swedish pharma company’s first-quarter earnings boosted by strong demand for cancer drugs
Trump’s tariffs have prompted businesses across the pond to question ties that have bound them to the US
London-listed drugmaker will establish research centre in Beijing
London-listed pharmaceuticals group expands investments in cancer cell therapies with EsoBiotec acquisition
